Author Archives: admin


Stem Cell Clinic > Articles by: admin

Intelligent Bio Solutions to Participate in the Noble Capital Markets’ 20th Annual Emerging Growth Equity Conference

By Embryonic Stem Cells

NEW YORK, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that its management team will present at the upcoming Noble Capital Markets’ 20th Annual Emerging Growth Equity Conference on December 3-4, 2024, in Boca Raton, FL.

More:
Intelligent Bio Solutions to Participate in the Noble Capital Markets’ 20th Annual Emerging Growth Equity Conference

Inotiv Ranked Number 138 Fastest-Growing Company in North America on the 2024 Deloitte Technology Fast 500™

By Embryonic Stem Cells

Acquiring and Developing Services and Resources to Build a Full Service, Customer-Focused CRO has Fueled 847% Revenue Growth Acquiring and Developing Services and Resources to Build a Full Service, Customer-Focused CRO has Fueled 847% Revenue Growth

Excerpt from:
Inotiv Ranked Number 138 Fastest-Growing Company in North America on the 2024 Deloitte Technology Fast 500™

Bluejay Therapeutics Announces Expansion of Leadership Team and Board of Directors

By Embryonic Stem Cells

SAN MATEO, Calif., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Bluejay Therapeutics, a clinical-stage biopharmaceutical company rapidly progressing transformative therapies for viral hepatitis and other serious liver diseases, today announced the expansion of its leadership team and board of directors.

Continue reading here:
Bluejay Therapeutics Announces Expansion of Leadership Team and Board of Directors

Vilya Announces Exclusive License Agreement of RFdiffusion-based Generative Model from the University of Washington for the Design of Macrocyclic…

By Embryonic Stem Cells

–  License of proprietary RFdiffusion-based model, RFpeptides, provides Vilya with another powerful structure prediction framework for rapid and unique design of potent and selective macrocycles for therapeutic applications

Excerpt from:
Vilya Announces Exclusive License Agreement of RFdiffusion-based Generative Model from the University of Washington for the Design of Macrocyclic...

Updated Phase 2 OraGrowtH Data Presented at ESPE 2024 Demonstrate Sustained Growth on Oral LUM-201 to 24 Months in PGHD and Correlation of Growth to…

By Embryonic Stem Cells

AUSTIN, Texas, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that new analyses of data from its Phase 2 OraGrowtH210 and OraGrowtH212 clinical trials were presented orally at the 62nd Annual European Society for Paediatric Endocrinology Meeting, or ESPE 2024, held November 16-18, 2024 in Liverpool, UK.

See the article here:
Updated Phase 2 OraGrowtH Data Presented at ESPE 2024 Demonstrate Sustained Growth on Oral LUM-201 to 24 Months in PGHD and Correlation of Growth to...

Chromocell Announces Name Change to “Channel Therapeutics Corporation” and Provides Therapeutic Program Updates

By Global News Feed

FREEHOLD, N.J., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation, (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, today announced that on November 18, 2024 it had changed its name to Channel Therapeutics Corporation (“Channel” or the “Company”), along with reincorporating in the State of Nevada. The Company believes the name change better reflects its focus on developing therapeutics based on sodium channel modulation and blockade for the treatment of pain.

The rest is here:
Chromocell Announces Name Change to “Channel Therapeutics Corporation” and Provides Therapeutic Program Updates

AscellaHealth Ranked Number 154 Fastest-Growing Company in North America on the 2024 Deloitte Technology Fast 500™

By Global News Feed

Attributes 753% Revenue Growth to Advancing Innovative Solutions for Life Sciences, Healthcare Organizations, Payers and Patients Attributes 753% Revenue Growth to Advancing Innovative Solutions for Life Sciences, Healthcare Organizations, Payers and Patients

See original here:
AscellaHealth Ranked Number 154 Fastest-Growing Company in North America on the 2024 Deloitte Technology Fast 500™

→←